6OE0
Benzensulfonamides bearing spyrohydantoin moieties act as potent inhibitors of human carbonic anhydrases II and VII and show neuropathic pain attenuating effects
6OE0 の概要
エントリーDOI | 10.2210/pdb6oe0/pdb |
分子名称 | Carbonic anhydrase 2, ZINC ION, 2-(2,4-dioxo-1,3-diazaspiro[4.6]undecan-3-yl)-N-(4-sulfamoylphenyl)acetamide, ... (5 entities in total) |
機能のキーワード | carbonic anhydrase inhibitors, metalloenzymes, organoselenium, lyase-lyase inhibitor complex, lyase/lyase inhibitor |
由来する生物種 | Homo sapiens (Human) |
タンパク質・核酸の鎖数 | 1 |
化学式量合計 | 29841.01 |
構造登録者 | |
主引用文献 | Angeli, A.,Di Cesare Mannelli, L.,Ghelardini, C.,Peat, T.S.,Bartolucci, G.,Menicatti, M.,Carta, F.,Supuran, C.T. Benzensulfonamides bearing spyrohydantoin moieties act as potent inhibitors of human carbonic anhydrases II and VII and show neuropathic pain attenuating effects. Eur.J.Med.Chem., 177:188-197, 2019 Cited by PubMed Abstract: Carbonic Anhydrases have been recently validated as novel therapeutic targets in neuropathic pain. In this study, we combine the anticonvulsant propriety of spyrohydantoin and the CA inhibitor moiety of benzenesulfonamide to synthesize a novel series of spyrohydantoin bearing sulfonamides with strong activity against hCA II and VII. These isoforms are present in the nervous system and largely expressed both at the central as well as at peripheral level and can be modulated for pain relief. The crystal structures of hCA II in complex with selected compounds 5a-c demonstrate the importance of the tail in the binding modes within the isoform. Finally, in vivo, in an animal model of oxaliplatin induced neuropathy, compounds with organoselenium tails (8b-c) showed potent neuropathic pain attenuating effects. Taken together, these data strongly suggest the translational utility of these inhibitors as novel pain relievers. PubMed: 31136893DOI: 10.1016/j.ejmech.2019.05.058 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (1.3 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード
